Journal
CANCER CELL
Volume 39, Issue 7, Pages 904-906Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2021.06.004
Keywords
-
Categories
Funding
- National Institutes of Health [R01CA231300, U54CA224081, R01CA204302, R01CA211052, R01CA169338]
Ask authors/readers for more resources
Relapse of AML patients to FLT3i treatment is a result of a long-term and stepwise process, where residual cancer cells initially survive and subsequently expand due to resistance. Joshi et al. demonstrate that early resistance to gilteritinib, driven by the microenvironment, evolves into mutation-driven late resistance through a multi-faceted approach.
Relapse of AML patients to FLT3i treatment is the result of a long-term and stepwise process leading to resistance, whereby residual cancer cells initially survive and subsequently expand. Here, Joshi et al. use a multi-faceted approach to characterize how microenvironment-driven early resistance to gilteritinib evolves into mutation-driven late resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available